Drug interactions in experimental hepatic porphyria. A model for the exacerbation by drugs of human variegate porphyria.
D000624:5-Aminolevulinate Synthetase / Q000378:metabolism; D000284:Administration, Oral; D000502:Allylisopropylacetamide; D000818:Animals; D002645:Chickens; D003035:Cobalt; D003998:Dicarboxylic Acids; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D006801:Humans; D007274:Injections, Intraperitoneal; D007982:Levulinic Acids / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D008930:Mitochondria, Liver / Q000378:metabolism; D008954:Models, Biological; D010634:Phenobarbital / Q000494:pharmacology; D011162:Porphobilinogen / Q000378:metabolism; D011164:Porphyrias / Q000139:chemically induced / Q000378:metabolism*; D011725:Pyridines; D051381:Rats; D013045:Species Specificity; D013050:Spectrometry, Fluorescence
D003998:Dicarboxylic Acids; D007982:Levulinic Acids; D011725:Pyridines; D000502:Allylisopropylacetamide; D003035:Cobalt; D011162:Porphobilinogen; D000624:5-Aminolevulinate Synthetase; D010634:Phenobarbital